GeneDx Holdings Corp. (WGS) stock
Close on Nov 16, 2026Market cap $1.52BP/E –Yield –
Earnings
GeneDx's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of GeneDx's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 22, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 9, 2026after the close | $123.10M | +5.5% | -$0.41 | $0.28 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 3, 2026during market hours | $114.40M | +11.4% | -$0.60 | $0.01 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 4, 2026during market hours | $102.30M | +17.5% | -$2.16 | -$0.28 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 23, 2026before the open | $121.00M | +27.0% | -$0.61 | $0.14 | Release |
| Q3 FY2025ended Sep 30, 2025 | Oct 28, 2025before the open | $116.70M | +51.8% | -$0.27 | $0.49 | Release |
| Q2 FY2025ended Jun 30, 2025 | Jul 29, 2025before the open | $102.70M | +45.7% | $0.36 | – | Release |
| Q1 FY2025ended Mar 31, 2025 | Apr 30, 2025before the open | $87.10M | +39.6% | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 18, 2025before the open | $95.30M | +66.0% | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Oct 29, 2024before the open | $76.90M | +44.3% | – | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Jul 30, 2024during market hours | $70.50M | +44.8% | -$1.10 | – | Release |
| Q1 FY2024ended Mar 31, 2024 | Apr 29, 2024during market hours | $62.40M | +44.8% | -$0.78 | – | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 20, 2024during market hours | $57.40M | -6.5% | – | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Oct 30, 2023during market hours | $53.30M | -35.9% | -$1.64 | – | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 8, 2023during market hours | $48.70M | +34.5% | -$1.84 | – | Release |
| Q1 FY2023ended Mar 31, 2023 | May 9, 2023during market hours | $43.10M | -20.0% | -$3.04 | – | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 14, 2023during market hours | $61.40M | – | – | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 14, 2022before the open | $83.20M | +92.6% | -$0.20 | – | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 15, 2022during market hours | $36.20M | – | -$0.25 | – | Release |
| Q1 FY2022ended Mar 31, 2022 | May 12, 2022during market hours | $53.90M | – | -$0.31 | – | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 14, 2022during market hours | – | – | -$0.17 | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 15, 2021during market hours | $43.20M | – | $0.15 | – | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 16, 2021during market hours | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
GeneDx's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Revenue | Q4 FY2026 | $135.00M | – | New | Nov 9, 2026 |
| Adjusted gross marginnon-GAAP | Q4 FY2026 | 71% | – | New | Nov 9, 2026 |
| Adjusted net incomenon-GAAP | Q4 FY2026 | $12.00M | – | New | Nov 9, 2026 |
| Exome and genome volume | Q4 FY2026 | 34,500 | – | New | Nov 9, 2026 |
| Exome and genome revenue | FY2026 | +17% | – | New | Nov 9, 2026 |
| Exome and genome revenue | FY2026 | +20% | – | New | Aug 3, 2026 |
| Revenue | FY2026 | $475.00M – $490.00M | – | New | Nov 9, 2026 |
| Revenue | FY2026 | $475.00M – $490.00M | $475.00M – $490.00M | Reaffirmed | Aug 3, 2026 |
| RevenueGAAP | FY2026 | $540.00M – $555.00M | – | New | Feb 23, 2026 |
| Adjusted gross marginnon-GAAP | FY2026 | 71% | 70% | Raised | Nov 9, 2026 |
| Adjusted gross marginnon-GAAP | FY2026 | 70% | 70% | Reaffirmed | Aug 3, 2026 |
| Adjusted net incomenon-GAAP | FY2026 | $12.00M | – | New | Nov 9, 2026 |
| Exome and genome volume | FY2026 | +28% | – | Lowered | Nov 9, 2026 |
| Exome and genome volume | FY2026 | +30% | – | Raised | Aug 3, 2026 |
| Growth in exome and genome revenue | FY2026 | +20% | +33% – +35% | Lowered | May 4, 2026 |
| Growth in exome and genome revenue | FY2026 | +33% – +35% | – | New | Feb 23, 2026 |
| Growth in exome and genome volume | FY2026 | +30% | +33% – +35% | Lowered | May 4, 2026 |
| Growth in exome and genome volume | FY2026 | +33% – +35% | – | Reaffirmed | Feb 23, 2026 |
Guidance vs results
The last range GeneDx gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| Q3 FY2026 | Revenue | $122.00M – $124.00M | $123.10M | Within range |
| Q2 FY2026 | Revenue | $110.00M – $112.00M | $114.40M | Above range |
| FY2025 | Revenue | $425.00M – $428.00M | $427.50MΣ4Q | Within range |
Guidance history
Every forecast GeneDx put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 9, 2026 | Adjusted gross margin | Q4 FY2026 | 71% | New |
| Nov 9, 2026 | Adjusted gross margin | FY2026 | 71% | Raised |
| Nov 9, 2026 | Exome and genome volume | Q4 FY2026 | 34,500 | New |
| Nov 9, 2026 | Adjusted net income | Q4 FY2026 | $12.00M | New |
| Nov 9, 2026 | Exome and genome volume | FY2026 | +28% | Lowered |
| Nov 9, 2026 | Adjusted net income | FY2026 | $12.00M | New |
| Nov 9, 2026 | Revenue | Q4 FY2026 | $135.00M | New |
| Nov 9, 2026 | Exome and genome revenue | Q4 FY2026 | $121.00M | Lowered |
| Nov 9, 2026 | Exome and genome revenue | FY2026 | +17% | New |
| Nov 9, 2026 | Revenue | FY2026 | $475.00M – $490.00M | New |
| Aug 3, 2026 | Adjusted gross margin | FY2026 | 70% | Reaffirmed |
| Aug 3, 2026 | Adjusted gross margin | Q3 FY2026 | 70% | New |
| Aug 3, 2026 | Exome and genome volume | FY2026 | +30% | Raised |
| Aug 3, 2026 | Exome and genome volume | Q3 FY2026 | 33,200 | New |
| Aug 3, 2026 | Adjusted net income | Q3 FY2026 | $2.00M | New |
| Aug 3, 2026 | Exome and genome revenue | FY2026 | +20% | New |
| Aug 3, 2026 | Revenue | FY2026 | $475.00M – $490.00M | Reaffirmed |
| Aug 3, 2026 | Revenue | Q3 FY2026 | $122.00M – $124.00M | New |
| Aug 3, 2026 | Exome and genome revenue | Q3 FY2026 | $110.00M – $112.00M | Lowered |
| May 4, 2026 | Adjusted gross margin | FY2026 | 70% | Reaffirmed |
| May 4, 2026 | Adjusted gross margin | Q2 FY2026 | 70% | New |
| May 4, 2026 | Growth in exome and genome volume | FY2026 | +30% | Lowered |
| May 4, 2026 | Growth in exome and genome revenue | FY2026 | +20% | Lowered |
| May 4, 2026 | Growth in exome and genome volume | Q2 FY2026 | 30,000 | New |
| May 4, 2026 | Growth in exome and genome revenue | Q2 FY2026 | $100.00M | New |
| May 4, 2026 | Adjusted net income (loss) | Q2 FY2026 | -$5.00M | New |
| May 4, 2026 | Revenue | FY2026 | $475.00M – $490.00M | Lowered |
| May 4, 2026 | Revenue | Q2 FY2026 | $110.00M – $112.00M | New |
| Feb 23, 2026 | Adjusted gross margin | FY2026 | 70% | New |
| Feb 23, 2026 | Growth in exome and genome revenue | FY2026 | +33% – +35% | New |
| Feb 23, 2026 | Growth in exome and genome volume | FY2026 | +33% – +35% | Reaffirmed |
| Feb 23, 2026 | Revenue | FY2026 | $540.00M – $555.00M | New |
| Jan 12, 2026 | Adjusted gross margin | FY2026 | 70% | New |
| Jan 12, 2026 | Growth in exome and genome revenue | FY2026 | +33% – +35% | New |
| Jan 12, 2026 | Growth in exome and genome volume | FY2026 | +33% – +35% | Reaffirmed |
| Jan 12, 2026 | Revenue | FY2026 | $540.00M – $555.00M | New |
| Oct 28, 2025 | Adjusted gross margin | FY2025 | 70% – 71% | New |
| Oct 28, 2025 | Growth in exome and genome revenue | FY2025 | +53% – +55% | New |
| Oct 28, 2025 | Revenue | FY2025 | $425.00M – $428.00M | New |
| Jul 29, 2025 | Adjusted gross margin | FY2025 | 68% – 71% | Raised |
| Jul 29, 2025 | Growth in exome and genome revenue | FY2025 | +48% – +52% | Raised |
| Jul 29, 2025 | Growth in exome and genome volume | FY2025 | +30% | Lowered |
| Jul 29, 2025 | Revenue | FY2025 | $400.00M – $415.00M | Raised |
| Apr 30, 2025 | Adjusted gross margins | FY2025 | 66% – 68% | Raised |
| Apr 30, 2025 | Growth in exome/genome volume and revenue | FY2025 | +30% | Reaffirmed |
| Apr 30, 2025 | Revenues | FY2025 | $360.00M – $375.00M | Raised |
| Feb 18, 2025 | Adjusted gross margins | FY2025 | 65% – 67% | New |
| Feb 18, 2025 | growth in exome/genome volume and revenue | FY2025 | +30% | New |
| Feb 18, 2025 | Revenues | FY2025 | $350.00M – $360.00M | New |
| Oct 29, 2024 | adjusted gross margin | FY2024 | 62% | Raised |
| Oct 29, 2024 | revenues | FY2024 | $284.00M – $290.00M | New |
| Jul 30, 2024 | adjusted gross margin profile | FY2024 | 60% | Reaffirmed |
| Jul 30, 2024 | net cash | FY2024 | $65.00M – $70.00M | Lowered |
| Jul 30, 2024 | revenues | FY2024 | $255.00M – $265.00M | New |
| Apr 29, 2024 | adjusted gross margin profile | FY2024 | 60% | Raised |
| Apr 29, 2024 | net cash | FY2024 | $70.00M – $80.00M | Lowered |
| Apr 29, 2024 | revenues | FY2024 | $235.00M – $245.00M | Raised |
| Feb 20, 2024 | adjusted gross margin profile | FY2024 | 50% | New |
| Feb 20, 2024 | net cash | FY2024 | $75.00M – $80.00M | New |
| Feb 20, 2024 | revenues | FY2024 | $220.00M – $230.00M | New |
| Oct 30, 2023 | net cash | FY2023 | $75.00M – $79.00M | Narrowed |
| Oct 30, 2023 | revenues | FY2023 | $187.00M – $192.00M | Lowered |
| Aug 8, 2023 | net cash | FY2023 | $70.00M – $85.00M | Lowered |
| Aug 8, 2023 | revenues | FY2023 | $205.00M – $220.00M | Reaffirmed |
| May 9, 2023 | net cash | FY2023 | $95.00M – $110.00M | New |
| May 9, 2023 | cash burn | FY2023 | $130.00M – $145.00M | Raised |
| May 9, 2023 | revenues | FY2023 | $205.00M – $220.00M | New |
| Mar 14, 2023 | net cash | FY2023 | $95.00M – $110.00M | Lowered |
| Mar 14, 2023 | cash burn | FY2023 | $130.00M – $145.00M | Raised |
| Mar 14, 2023 | revenues | FY2023 | $205.00M – $220.00M | Reaffirmed |
| Jan 9, 2023 | use of cash for continuing operations | FY2023 | $95.00M – $110.00M | New |
| Jan 9, 2023 | cash burn | FY2023 | $130.00M – $145.00M | Raised |
| Jan 9, 2023 | revenues | FY2023 | $205.00M – $220.00M | New |
| Nov 14, 2022 | adjusted gross margin | FY2022 | 4% – 9% | Lowered |
| Nov 14, 2022 | adjusted gross margin | FY2022 | 15% – 20% | Raised |
| Nov 14, 2022 | reported revenue | FY2022 | $245.00M – $255.00M | Reaffirmed |
| Nov 14, 2022 | reported revenue | FY2022 | $154.00M – $164.00M | Lowered |
| Aug 15, 2022 | adjusted gross margin | FY2022 | 4% – 9% | Lowered |
| Aug 15, 2022 | adjusted gross margin | FY2022 | 15% – 20% | Raised |
| Aug 15, 2022 | revenue | FY2022 | $154.00M – $164.00M | Lowered |
| Aug 15, 2022 | reported revenue | FY2022 | $245.00M – $255.00M | Lowered |
| May 12, 2022 | gross margin | FY2022 | 20% | Raised |
| May 12, 2022 | total revenue | FY2022 | $305.00M – $315.00M | New |
| May 12, 2022 | pro forma revenue target | FY2022 | $350.00M | New |
| Mar 14, 2022 | adjusted gross margin | FY2022 | 10% | New |
| Mar 14, 2022 | resulted test volume growth | FY2022 | +20% | New |
| Mar 14, 2022 | total revenue | FY2022 | $215.00M – $225.00M | New |
| Nov 15, 2021 | resulted volume | Q4 FY2021 | 73,000 – 79,000 | New |
| Nov 15, 2021 | total revenue | FY2021 | $201.00M – $204.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases GeneDx filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Results
- Results
- Results
- Update
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
See a number that looks wrong?